How do you convince a brand manager to try a new or unproven approach? Who will be the guinea pig and invest in Web 2.0, or any of the other programs like online sampling and virtual speaker programs? New programs may get a lot of buzz, but implementing them takes a client willing to assume some risk. When a client really needs to focus their resources, we advise them to first do what is tried and true. There is a time for innovation, but there is also a time for doing what you know works.
How do you convince a brand manager to try a new or unproven approach? Who will be the guinea pig and invest in Web 2.0, or any of the other programs like online sampling and virtual speaker programs? New programs may get a lot of buzz, but implementing them takes a client willing to assume some risk. When a client really needs to focus their resources, we advise them to first do what is tried and true. There is a time for innovation, but there is also a time for doing what you know works.
Biopharma's marketing needs are unique in both size and scope. They demand specific knowledge and therapeutic expertise. They require the ability to identify and test smaller, measurable programs, but also must possess the scalability to expand these programs when they prove successful. They need to leverage those marketing programs and vehicles that: target and communicate to/with different target audiences; explain complicated medical and scientific issues; educate clinicians and patients on the proper use of their solutions across different therapeutic areas and, where appropriate, in conjunction with other forms of therapy; provide direct communication to enhance product prescribing and compliance; and extend support and/or augment sales force coverage.
Compass Healthcare Communications is an independent interactive and relationship marketing agency.
Telephone: 609-688-8440
E-mail: contact@compasshc.com
Web site: compasshc.com
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.